Abstract
Summary Like Mesbah Ardakani et al. we investigated the impact of BRAF V600E allele frequency (AF) on progression free survival (PFS) and overall survival (OS) in patients treated by BRAF inhibitors used as single agents for advanced or metastatic melanoma but we used a larger retrospective cohort with 78 patients enrolled in two skin cancer centers. Because BRAF mutation has a heterozygous pattern, we set the cutoff to separate high and low BRAF AF at 60%, in accordance to our previous work on this subject. Like Mesbah Ardakani et al., a high BRAF V600E AF did not significantly influence PFS or OS, but in our study there was a trend towards better clinical outcomes. Further larger studies with a cutoff of 60% are needed to definitely conclude if BRAF AF is a biomarker of response to BRAF inhibitors used as single agents as well as used in combination regimens. This article is protected by copyright. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
